March 18, 2025 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD ...

Nipocalimab led to sustained MG-ADL and QMG improvements over 84 weeks with long-term IgG reduction in gMG patients. 45% of ...

If the FDA approves nipocalimab, the long-term data could form part of J&J’s pitch for the gMG market. The labels for ...

J&J exhibited additional findings from the Vivacity-MG3 study, displaying that nipocalimab met its key secondary endpoint.

SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies.

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjögren's disease (SjD), an autoimmune condition that affects millions of people ...

Johnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, nipocalimab, for treating adult patients with moderate-to-severe Sjögren ...

Innovative Medicine: nipocalimab in gMG; RYBREVANT Sub-Q in NSCLC; TREMFYA Sub-Q in UC; TAR-200 NMIBC; icotrokinra in PsO and UC; RYBREVANT in ...

The additional analysis confirmed that patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their Myasthenia Gravis Activities of Daily Living (MG-ADL ...

Innovative Medicine: nipocalimab in gMG; RYBREVANT Sub-Q in NSCLC; TREMFYA Sub-Q in UC; TAR-200 NMIBC; icotrokinra in PsO and UC; RYBREVANT in HNC; CAPLYTA in aMDD. MedTech: OTTAVA progression ...